<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01665274</url>
  </required_header>
  <id_info>
    <org_study_id>GCPCT1205/repeat</org_study_id>
    <nct_id>NCT01665274</nct_id>
  </id_info>
  <brief_title>Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer</brief_title>
  <acronym>repeat</acronym>
  <official_title>A Randomized Single Center Controlled Study of Perioperative Chemotherapy of Oxaliplatin Combined With Capecitabine (XELOX) Versus XELOX as Post-operative Chemotherapy in Advanced Gastric Adenocarcinoma With D2 Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that capecitabine/oxaliplatin as perioperative
      chemotherapy is superior or not to operation directly for locally advanced gastric cancer in
      terms of 3 year disease-free survival (DFS) rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients of gastric cancer have been divided into two parts in random.The test group
      receive perioperative chemotherapy (XELOX) six cycles and the control group administrate the
      same program after operation. The two groups have the same staging and eligibility
      criteria.The 3 year disease-free survival (DFS) rate and 5 year overall survival (OS) rate
      maybe the last evaluation standard.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year DFS</measure>
    <time_frame>3 years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>From date of randomization until the end of the study, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>evaluate after the end of neoadjuvant chemotherapy ie within 1 weeks after the neoadjuvant therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>after the pathological examination of resected speciments ie within 1 month after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX adjuvant group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D2 resection
XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX neoadjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy before operation.
D2 resection
After operation:
CR/PR: XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy after operation. SD/PD:,ST(Drug: S-1，40-75mg twice daily. d1-14 q3w Drug: Paclitaxel IV infusion 135mg/m2 d1; q3w) 3 cycles chemotherapy after operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1,000 mg/m² twice daily, d1-14, q3w</description>
    <arm_group_label>XELOX adjuvant group</arm_group_label>
    <arm_group_label>XELOX neoadjuvant</arm_group_label>
    <other_name>xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin IV infusion, 130mg/m² d1, q3w</description>
    <arm_group_label>XELOX adjuvant group</arm_group_label>
    <arm_group_label>XELOX neoadjuvant</arm_group_label>
    <other_name>eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 resection</intervention_name>
    <description>D2 resection</description>
    <arm_group_label>XELOX adjuvant group</arm_group_label>
    <arm_group_label>XELOX neoadjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky performance status of ≥60 %.

          -  Histologically confirmed gastric adenocarcinoma, staged pathologically or clinically,
             stage cT2-4N+M0, and cT4N0M0.

          -  Patients had to have adequate renal function (serum creatinine ≤1 times the upper
             limit of normal [ULN]), hepatic function (total bilirubin ≤1·5 times the ULN,
             aspartate or alanine aminotransferase ≤2·5 times the ULN, alkaline phosphatase ≤2·5
             times the ULN, Serum albumin ≥30g/L), and haematological function (absolute neutrophil
             count ≥1·5×10⁹/L and platelet count ≥100×10⁹/L)

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  According to the AJCC TMN 7.0, Any evidence of metastatic (TxNxM1) patients(including
             presence of tumor cells in the ascites).

          -  Sexually active males and females (of childbearing potential) unwilling to practice
             contraception during the study.

          -  Previous cytotoxic chemotherapy, radiotherapy or immunotherapy except corticosteroids,
             for the currently treated gastric cancer.

          -  Has uncontrolled epilepsy, central nervous system diseases or mental disorders of
             history.

          -  Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery
             disease, New York Heart Association (NYHA) grade II or greater congestive heart
             failure or serious cardiac arrhythmia requiring medication or myocardial infarction
             within the last 12 months.

          -  Lack of physical integrity of the upper gastrointestinal tract or those who have
             malabsorption syndrome likely to influence absorption of capecitabine, or inability to
             take oral medication.

          -  Known peripheral neuropathy ≥ CTCAEv3 grade 1 (Common Terminology for Adverse Events).
             Absence of deep tendon reflexes as the sole neurologic abnormality does not render the
             patient ineligible.

          -  Organ allografts requiring immunosuppressive therapy.

          -  Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant
             disease.

          -  Moderate or severe renal impairment [creatinine clearance equal to or below 50 ml/min
             (calculated according to Cockroft and Gault)], or serum creatinine &gt; 1.5 x upper limit
             of normal (ULN).

          -  Any of the following laboratory values:

               -  Absolute neutrophil count (ANC) &lt; 1.5 x 109/L

               -  Platelet count &lt; 100 x 109/L

               -  Total bilirubin &gt; 1.5 x ULN

               -  ALAT, ASAT &gt; 2.5 x ULN

               -  Alkaline phosphatase &gt; 2.5 x ULN.

          -  Prior unanticipated severe reaction to fluoropyrimidine therapy (with or without
             documented dihydropyrimidine dehydrogenase (DPD) deficiency) or patients with known
             DPD deficiency.

          -  Hypersensitivity to platinum compounds or any of the components of the study
             medications.

          -  Received any investigational drug or agent/procedure, i.e. participation in another
             trial, within 4 weeks before randomization.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingwei Xue, Phd, MD</last_name>
    <role>Study Director</role>
    <affiliation>Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingwei Xue, Phd, MD</last_name>
    <email>xyw801@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Ha er Bin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingwei Xue, Phd, MD</last_name>
      <email>xyw801@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2012</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yingwei Xue</investigator_full_name>
    <investigator_title>Chief of Gastrointestinal Surgery</investigator_title>
  </responsible_party>
  <keyword>xelox</keyword>
  <keyword>advanced gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

